Bioatla (BCAB) Q3 2025 earnings summary

Executive summary

• Focused on developing conditionally active biologics (CABs) for solid tumors, leveraging a proprietary platform with over 500 patents and advancing multiple clinical programs, including BA3182, Ozuriftamab Vedotin, Mecbotamab Vedotin, and Evalstotug.

• Achieved FDA alignment on Phase 3 Oz-V trial design for 2L+ OPSCC, enabling dual primary endpoints and potential accelerated approval.

• Advanced stages of finalizing a strategic partnership transaction, expected to close by year end.

• Achieved milestone payment through Context Therapeutics for CAB-Nectin4-TCE, validating the CAB T-cell engager platform.

• Implemented a 30% workforce reduction and reduced lease footprint to lower costs and extend cash runway.

Financial highlights

• Cash and cash equivalents were $8.3 million as of September 30, 2025, excluding a $2 million milestone payment received in October.

• Net loss was $15.8 million for Q3 2025, compared to $10.6 million in Q3 2024, with prior year including $11 million in collaboration revenue.

• R&D expenses decreased to $9.5 million from $16.4 million year-over-year, driven by program prioritization and workforce reduction.

• G&A expenses declined to $4.2 million from $5.9 million year-over-year, reflecting lower personnel and stock-based compensation costs.

• No revenue recognized in Q3 or YTD 2025; $11 million revenue recognized in Q3 and YTD 2024 from a licensing agreement.

Outlook and guidance

• R&D expenses expected to continue declining through 2025 as resources are concentrated on prioritized programs.

• Readout from BA3182 trial anticipated in the first half of 2026, with further expansion data later in 2026.

• Initiation of Oz-V Phase 3 study in 2L+ OPSCC planned with a strategic partner in early 2026.

• Current cash may not be sufficient to fund operations for 12 months; additional capital will be required.

• Management is exploring equity, debt, and strategic collaborations for funding.